Georgia Research Alliance

Focused Cryo is a healthcare company that develops a smart cryoablation system that provides better spatiotemporal control. These benefits represent a significant improvement in the treatment of Type 2 diabetes, obesity, and other ailments that are addressed with the cryoablation of nerves and ganglia. The company is based in Kennesaw, Georgia.

Focused Cryo is a healthcare company that develops a smart cryoablation system that provides better spatiotemporal control. These benefits represent a significant improvement in the treatment of Type 2 diabetes, obesity, and other ailments that are addressed with the cryoablation of nerves and ganglia. The company is based in Kennesaw, Georgia.

Focused Cryo is a healthcare company that develops a smart cryoablation system that provides better spatiotemporal control. These benefits represent a significant improvement in the treatment of Type 2 diabetes, obesity, and other ailments that are addressed with the cryoablation of nerves and ganglia. The company is based in Kennesaw, Georgia.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in the development of real-time cellular activity monitors for drug discovery and biological research. The company focuses on providing innovative systems that enable researchers in academic institutions and pharmaceutical companies to conduct continuous and non-invasive analysis of cellular behavior. Its flagship technology, RESIPHER, utilizes proprietary high-resolution optical oxygen sensors to measure oxygen consumption in standard multi-well plates. This tool streams real-time data to a user-friendly web application, allowing researchers to gain valuable insights into the cellular environment directly from the incubator, thereby enhancing the efficiency of cell culture experiments.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in the development of real-time cellular activity monitors for drug discovery and biological research. The company focuses on providing innovative systems that enable researchers in academic institutions and pharmaceutical companies to conduct continuous and non-invasive analysis of cellular behavior. Its flagship technology, RESIPHER, utilizes proprietary high-resolution optical oxygen sensors to measure oxygen consumption in standard multi-well plates. This tool streams real-time data to a user-friendly web application, allowing researchers to gain valuable insights into the cellular environment directly from the incubator, thereby enhancing the efficiency of cell culture experiments.

MapHabit, Inc. is a company that specializes in developing solutions for individuals with memory impairments by utilizing visual maps to engage the brain's habit system and foster healthy routines. Founded in 2018 and based in Decatur, Georgia, MapHabit offers a mobile app that enables patients, their families, and care providers to create, track, and share personalized daily plans and activities. The app also provides valuable data analytics for care providers, facilitating research and the establishment of localized support groups and customized events. By offering a personalized, visual task mapping system, MapHabit simplifies care management for both patients and providers, helping individuals with various disorders navigate their daily activities effectively.

MapHabit, Inc. is a company that specializes in developing solutions for individuals with memory impairments by utilizing visual maps to engage the brain's habit system and foster healthy routines. Founded in 2018 and based in Decatur, Georgia, MapHabit offers a mobile app that enables patients, their families, and care providers to create, track, and share personalized daily plans and activities. The app also provides valuable data analytics for care providers, facilitating research and the establishment of localized support groups and customized events. By offering a personalized, visual task mapping system, MapHabit simplifies care management for both patients and providers, helping individuals with various disorders navigate their daily activities effectively.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in the development of real-time cellular activity monitors for drug discovery and biological research. The company focuses on providing innovative systems that enable researchers in academic institutions and pharmaceutical companies to conduct continuous and non-invasive analysis of cellular behavior. Its flagship technology, RESIPHER, utilizes proprietary high-resolution optical oxygen sensors to measure oxygen consumption in standard multi-well plates. This tool streams real-time data to a user-friendly web application, allowing researchers to gain valuable insights into the cellular environment directly from the incubator, thereby enhancing the efficiency of cell culture experiments.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company based in Atlanta, Georgia, founded in 2007. The company specializes in the discovery and development of novel therapeutics aimed at treating inflammatory diseases, including cystic fibrosis and moderately severe acne. Its lead product, CTX-4430, is a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells. Celtaxsys also focuses on manipulating immune cell migration and activation to develop treatments for cancer, inflammatory conditions, and autoimmune diseases. Through its innovative approach, the company aims to provide effective therapies for patients suffering from rare and serious inflammatory disorders.

NatGlycan is a biotech corporation focusing on large-scale natural glycans. It introduces proprietary glycan extraction techniques making possible the large-scale preparation of natural glycans. NatGlycan is dedicated to providing high-quality glycans and technical services to industry and the community. The company was co-founded by two preeminent professors at Emory University in Atlanta USA.

Urjanet, Inc. is a company that specializes in providing a cloud-based platform for automated access to utility data. Founded in 2009 and headquartered in Atlanta, Georgia, with an additional location in Chennai, India, Urjanet connects directly to utility providers to acquire and normalize utility bills and interval data. Its offerings include automated access to utility bill data across various utilities, granular measurements of energy consumption, and advanced metering infrastructure data without requiring additional hardware or software. The platform also features capabilities for weather data analysis and alerts for billing and consumption anomalies. Urjanet's solutions are designed to improve business intelligence, energy management, accounting, and procurement processes for organizations, enabling them to enhance financial performance, energy efficiency, and sustainability.

NatGlycan is a biotech corporation focusing on large-scale natural glycans. It introduces proprietary glycan extraction techniques making possible the large-scale preparation of natural glycans. NatGlycan is dedicated to providing high-quality glycans and technical services to industry and the community. The company was co-founded by two preeminent professors at Emory University in Atlanta USA.

MoQuality Inc. is a technology company founded in 2014 and headquartered in Atlanta, Georgia, that specializes in artificial intelligence-driven mobile testing solutions. The company focuses on enhancing the application development process by providing tools that allow developer teams to create, run, and maintain tests efficiently. MoQuality's flagship product, Barista, offers a scriptless test automation experience, leveraging AI to generate user-centric test scenarios for mobile applications. This platform enables developers to conduct comprehensive end-to-end UI testing across various devices and operating systems, ensuring that applications are thoroughly vetted before reaching consumers. By streamlining the testing process, MoQuality aims to help developers deliver higher-quality apps and improve overall user experiences.

Accuitis, Inc. is a pre-clinical-stage biopharmaceutical company focused on acquiring, developing, and marketing innovative pharmaceuticals for niche, orphan, and underserved disease states. Founded in 2011, the company is headquartered in Alpharetta, Georgia. Accuitis specializes in the development of drug therapies for conditions such as rosacea and other topical skin diseases, as well as therapeutics for skin aging, acne, and dry eye. Through its targeted approach, Accuitis aims to address significant unmet medical needs in these areas.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

LymphaTech, Inc. is a healthcare technology company based in Atlanta, Georgia, focused on the treatment and prevention of lymphedema. Founded in 2014, the company has developed an innovative 3D body scanning technology that enables healthcare professionals to diagnose lymphedema more effectively and promptly. The device measures limb circumference to create accurate three-dimensional models, allowing for the monitoring of geometric changes over time. This technology can be utilized both in clinical settings and at home, facilitating early detection of symptoms and enabling timely intervention. By providing an easy-to-use mobile platform powered by proprietary algorithms, LymphaTech aims to enhance the quality of life for patients, particularly breast cancer survivors, while meeting critical needs in the healthcare community.

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing treatments for serious eye diseases with the aim of restoring and preserving vision. Founded in 2011 and headquartered in Alpharetta, Georgia, the company specializes in a proprietary ocular microinjection platform that allows for targeted delivery of therapeutic products to specific compartments of the eye. This innovative approach includes the use of the SCS Microinjector for administering therapies directly into the suprachoroidal space, enabling a non-surgical, repeatable procedure. Among its product pipeline, Clearside is developing XIPERE, a triamcinolone acetonide injectable suspension for macular edema, and CLS-AX, an axitinib for suprachoroidal injection. The company is dedicated to advancing pharmacological therapies for sight-threatening conditions by ensuring precise and effective treatment delivery.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

Cambium Medical Technologies, established by a team of experts from Emory University in Atlanta, Georgia, focuses on developing and commercializing regenerative therapies using processed human platelets. The company is working on Elate Ocular, which is a standardized biologic eye drop aimed at treating dry eye syndrome, also known as keratoconjunctivitis sicca. Currently, Elate Ocular is an investigational drug and has not yet received FDA approval for sale in the United States or elsewhere. Cambium Medical Technologies aims to address diseases and conditions related to aging or damage through its innovative platelet-derived therapies.

MedShape is a privately held medical device company founded in 2005 based on a portfolio of proprietary surgical solutions that use its patented adaptive shape memory healing technologies to address the increasing demand for improved joint fusion, sports medicine, and musculoskeletal trauma products. MedShape® has enjoyed long-term support from Hills Capital Management, the Georgia Research Alliance (GRA), the National Science Foundation (NSF), the National Institutes of Health (NIH), and In-Q-Tel.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

Metaclipse Therapeutics is an early-stage biotechnology company based in Atlanta, Georgia, founded in 2010. The company specializes in developing novel cancer therapies aimed at activating the body's immune system to attack metastatic cancer cells. Its primary product, MembrexTM, is a personalized immunotherapy tailored to each patient and their specific tumor. This therapy involves creating nano-size vesicles from the patient's tumor tissue, which are then augmented with immunostimulatory proteins using a proprietary method. These modified vesicles are administered dermally to deliver both immunostimulatory proteins and tumor-specific antigens to the immune system, fostering robust tumor-specific immunity. Metaclipse Therapeutics intends to commercialize its products through licensing agreements with major pharmaceutical companies after establishing safety and effectiveness. The company's therapies are designed to treat various cancer types, including breast cancer, prostate cancer, renal cancer, melanoma, lymphoma, and ovarian cancer.

Metaclipse Therapeutics is an early-stage biotechnology company based in Atlanta, Georgia, founded in 2010. The company specializes in developing novel cancer therapies aimed at activating the body's immune system to attack metastatic cancer cells. Its primary product, MembrexTM, is a personalized immunotherapy tailored to each patient and their specific tumor. This therapy involves creating nano-size vesicles from the patient's tumor tissue, which are then augmented with immunostimulatory proteins using a proprietary method. These modified vesicles are administered dermally to deliver both immunostimulatory proteins and tumor-specific antigens to the immune system, fostering robust tumor-specific immunity. Metaclipse Therapeutics intends to commercialize its products through licensing agreements with major pharmaceutical companies after establishing safety and effectiveness. The company's therapies are designed to treat various cancer types, including breast cancer, prostate cancer, renal cancer, melanoma, lymphoma, and ovarian cancer.

Cambium Medical Technologies, established by a team of experts from Emory University in Atlanta, Georgia, focuses on developing and commercializing regenerative therapies using processed human platelets. The company is working on Elate Ocular, which is a standardized biologic eye drop aimed at treating dry eye syndrome, also known as keratoconjunctivitis sicca. Currently, Elate Ocular is an investigational drug and has not yet received FDA approval for sale in the United States or elsewhere. Cambium Medical Technologies aims to address diseases and conditions related to aging or damage through its innovative platelet-derived therapies.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia, that serves a diverse clientele, including the pharmaceutical, biotechnology, clinical, academic, and government sectors. Established in 2010, the company specializes in clinical trials, diagnostic testing, and research, with a particular focus on oncology and personalized medicine. AKESOgen offers a wide range of services, including high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (both NGS and Sanger), genotyping, and epigenomic analysis, all conducted to CLIA/GLP standards. Additionally, the company provides clinical and regulatory services, ensuring compliance with clinical trial protocols and molecular pathology. Its notable clients include the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente.

Metaclipse Therapeutics is an early-stage biotechnology company based in Atlanta, Georgia, founded in 2010. The company specializes in developing novel cancer therapies aimed at activating the body's immune system to attack metastatic cancer cells. Its primary product, MembrexTM, is a personalized immunotherapy tailored to each patient and their specific tumor. This therapy involves creating nano-size vesicles from the patient's tumor tissue, which are then augmented with immunostimulatory proteins using a proprietary method. These modified vesicles are administered dermally to deliver both immunostimulatory proteins and tumor-specific antigens to the immune system, fostering robust tumor-specific immunity. Metaclipse Therapeutics intends to commercialize its products through licensing agreements with major pharmaceutical companies after establishing safety and effectiveness. The company's therapies are designed to treat various cancer types, including breast cancer, prostate cancer, renal cancer, melanoma, lymphoma, and ovarian cancer.

Cambium Medical Technologies, established by a team of experts from Emory University in Atlanta, Georgia, focuses on developing and commercializing regenerative therapies using processed human platelets. The company is working on Elate Ocular, which is a standardized biologic eye drop aimed at treating dry eye syndrome, also known as keratoconjunctivitis sicca. Currently, Elate Ocular is an investigational drug and has not yet received FDA approval for sale in the United States or elsewhere. Cambium Medical Technologies aims to address diseases and conditions related to aging or damage through its innovative platelet-derived therapies.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia, that serves a diverse clientele, including the pharmaceutical, biotechnology, clinical, academic, and government sectors. Established in 2010, the company specializes in clinical trials, diagnostic testing, and research, with a particular focus on oncology and personalized medicine. AKESOgen offers a wide range of services, including high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (both NGS and Sanger), genotyping, and epigenomic analysis, all conducted to CLIA/GLP standards. Additionally, the company provides clinical and regulatory services, ensuring compliance with clinical trial protocols and molecular pathology. Its notable clients include the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente.

NeurOp Corporation is a biopharmaceutical company founded in 2002 and headquartered in Atlanta, Georgia. It focuses on developing treatments for central nervous system disorders at the preclinical stage. NeurOp's research targets the GluN2B subunit of neuronal NMDA receptors to create disease-activated small molecules for indications such as ischemia (stroke), neuropathic pain, Parkinson's disease, Alzheimer's disease, and treatment-resistant depression.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia, that serves a diverse clientele, including the pharmaceutical, biotechnology, clinical, academic, and government sectors. Established in 2010, the company specializes in clinical trials, diagnostic testing, and research, with a particular focus on oncology and personalized medicine. AKESOgen offers a wide range of services, including high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (both NGS and Sanger), genotyping, and epigenomic analysis, all conducted to CLIA/GLP standards. Additionally, the company provides clinical and regulatory services, ensuring compliance with clinical trial protocols and molecular pathology. Its notable clients include the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia, that serves a diverse clientele, including the pharmaceutical, biotechnology, clinical, academic, and government sectors. Established in 2010, the company specializes in clinical trials, diagnostic testing, and research, with a particular focus on oncology and personalized medicine. AKESOgen offers a wide range of services, including high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (both NGS and Sanger), genotyping, and epigenomic analysis, all conducted to CLIA/GLP standards. Additionally, the company provides clinical and regulatory services, ensuring compliance with clinical trial protocols and molecular pathology. Its notable clients include the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente.

Whisper Communications is an Atlanta-based company that specializes in wireless networking services, leveraging innovative technologies to enhance data security. Utilizing patent-pending technology developed at the Georgia Institute of Technology, Whisper has created an encoding methodology that ensures data signals transmitted beyond a designated area, referred to as the "cone of silence," are rendered useless to eavesdroppers. The company's approach focuses on physical layer security, where the safety of data is intrinsically linked to its proximity to the data source. This enables IT companies to effectively monitor, track, and control devices located within a fixed area, thereby enhancing the overall security of wireless communications.

NeurOp Corporation is a biopharmaceutical company founded in 2002 and headquartered in Atlanta, Georgia. It focuses on developing treatments for central nervous system disorders at the preclinical stage. NeurOp's research targets the GluN2B subunit of neuronal NMDA receptors to create disease-activated small molecules for indications such as ischemia (stroke), neuropathic pain, Parkinson's disease, Alzheimer's disease, and treatment-resistant depression.

Metaclipse Therapeutics is an early-stage biotechnology company based in Atlanta, Georgia, founded in 2010. The company specializes in developing novel cancer therapies aimed at activating the body's immune system to attack metastatic cancer cells. Its primary product, MembrexTM, is a personalized immunotherapy tailored to each patient and their specific tumor. This therapy involves creating nano-size vesicles from the patient's tumor tissue, which are then augmented with immunostimulatory proteins using a proprietary method. These modified vesicles are administered dermally to deliver both immunostimulatory proteins and tumor-specific antigens to the immune system, fostering robust tumor-specific immunity. Metaclipse Therapeutics intends to commercialize its products through licensing agreements with major pharmaceutical companies after establishing safety and effectiveness. The company's therapies are designed to treat various cancer types, including breast cancer, prostate cancer, renal cancer, melanoma, lymphoma, and ovarian cancer.

NeurOp Corporation is a biopharmaceutical company founded in 2002 and headquartered in Atlanta, Georgia. It focuses on developing treatments for central nervous system disorders at the preclinical stage. NeurOp's research targets the GluN2B subunit of neuronal NMDA receptors to create disease-activated small molecules for indications such as ischemia (stroke), neuropathic pain, Parkinson's disease, Alzheimer's disease, and treatment-resistant depression.

NeurOp Corporation is a biopharmaceutical company founded in 2002 and headquartered in Atlanta, Georgia. It focuses on developing treatments for central nervous system disorders at the preclinical stage. NeurOp's research targets the GluN2B subunit of neuronal NMDA receptors to create disease-activated small molecules for indications such as ischemia (stroke), neuropathic pain, Parkinson's disease, Alzheimer's disease, and treatment-resistant depression.

NeurOp Corporation is a biopharmaceutical company founded in 2002 and headquartered in Atlanta, Georgia. It focuses on developing treatments for central nervous system disorders at the preclinical stage. NeurOp's research targets the GluN2B subunit of neuronal NMDA receptors to create disease-activated small molecules for indications such as ischemia (stroke), neuropathic pain, Parkinson's disease, Alzheimer's disease, and treatment-resistant depression.

NeurOp Corporation is a biopharmaceutical company founded in 2002 and headquartered in Atlanta, Georgia. It focuses on developing treatments for central nervous system disorders at the preclinical stage. NeurOp's research targets the GluN2B subunit of neuronal NMDA receptors to create disease-activated small molecules for indications such as ischemia (stroke), neuropathic pain, Parkinson's disease, Alzheimer's disease, and treatment-resistant depression.